Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Cash (2020 - 2025)

Historic Change in Cash for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to -$10.7 million.

  • RxSight's Change in Cash fell 3880.91% to -$10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 8869.3%. This contributed to the annual value of $7.1 million for FY2024, which is 42176.09% up from last year.
  • Latest data reveals that RxSight reported Change in Cash of -$10.7 million as of Q3 2025, which was down 3880.91% from $12.4 million recorded in Q2 2025.
  • Over the past 5 years, RxSight's Change in Cash peaked at $26.5 million during Q3 2021, and registered a low of -$43.7 million during Q4 2021.
  • In the last 5 years, RxSight's Change in Cash had a median value of -$128000.0 in 2022 and averaged $838263.2.
  • The largest annual percentage gain for RxSight's Change in Cash in the last 5 years was 540940.0% (2021), contrasted with its biggest fall of 284290.2% (2021).
  • Over the past 5 years, RxSight's Change in Cash (Quarter) stood at -$43.7 million in 2021, then skyrocketed by 106.58% to $2.9 million in 2022, then crashed by 105.78% to -$166000.0 in 2023, then soared by 114.46% to $24000.0 in 2024, then plummeted by 44779.17% to -$10.7 million in 2025.
  • Its Change in Cash was -$10.7 million in Q3 2025, compared to $12.4 million in Q2 2025 and $11.3 million in Q1 2025.